You should think again about how 4 RAs affect and influence the FDA. A safe and effective approved DCVAX therapy for GBM in the U.K. and Europe could lead to a survival discrepancy across continents. This would eventually undermine the business of American medicine as people would seek treatment exclusively in Europe for GBM. That’s a bad look on the FDA.